Seminars in Oncology
Volume 29, Issue 2 , Pages 119-125, April 2002

Intrahepatic arterial infusion of chemotherapy: Pharmacologic principles☆☆

Departments of Internal Medicine and Pharmacology, University of Michigan Health System, Ann Arbor, MI.

Abstract 

Hepatic arterial (HA) infusional chemotherapy possesses a number of constraints not found with systemic chemotherapy. The drug used should have activity in a dose-responsive way without significant hepatic toxicity. The drug must also possess suitable pharmacokinetic properties, namely, a high total body clearance and hepatic extraction, so as to generate high hepatic and low systemic exposures. Of the drugs examined for HA use, 5-fluoro-2'-deoxyuridine (FUDR, floxuridine) demonstrates the best properties. In HA infusional therapy, the catheter is positioned to deliver drug directly to the liver only and must be connected to a reliable pumping mechanism. Surgical implantation of catheters and pumps provides a safe and reliable means to infuse HA FUDR. HA FUDR delivery via an implanted system in the treatment of colorectal liver metastases represents the largest application of HA therapy and provides a basis for future advances when combined with other regional and systemic treatments. Semin Oncol 29:119-125. Copyright 2002, Elsevier Science (USA). All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 W.D.E. has been a consultant to the Arrow Therex Corp, Walpole, MA.

☆☆ Address reprint requests to William D. Ensminger, MD, PhD, Departments of Internal Medicine and Pharmacology, University of Michigan Health System, Ann Arbor, MI 48109-0504.

PII: S0093-7754(02)50132-9

doi:10.1053/sonc.2002.31679

Seminars in Oncology
Volume 29, Issue 2 , Pages 119-125, April 2002